In a 2016 analysis of 106 drug candidates evaluated in clinical trials, the total capital expenditure incurred by a manufacturer to get a drug approved in successful Phase III trials was $2.6 billion ( in 2013 dollars), an amount increasing at an annual rate of 8.5%.
Katika ukaguzi mwaka wa 2016 wa dawa 106 zilizoteuliwa na kutathminiwa kupitia vipimo vya kliniki, matumizi ya jumla ya mtaji kwa mtengenezaji mwenye dawa ilidhibitishwa kupitia vipimo vilivyofaulu vya Awamu ya III yalikuwa dola bilioni 2.6 (kwa dola za mwaka wa 2013), kiasi cha fedha kinachoongezeka kwa kiwango cha kila mwaka cha asilimia 8.5.